Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 38 Genitourinary 16 Gastrointestinal 13 Breast 10 Thoracic 8 Other solid neoplasm 6 Head & Neck 5 CNS 5 Tumor-Agnostic 4 Sarcoma 3 Dermatologic 3 Lymphoid 1 Endocrine 1 Classical hematology 1

Conditions

Interventions

Rituximab 689 Cyclophosphamide 614 Vincristine 285 Etoposide 272 Doxorubicin 271 Cytarabine 230 Prednisone 228 Methotrexate 221 fludarabine phosphate 189 Filgrastim 187 Dexamethasone 180 fludarabine 175 Lenalidomide 165 Radiotherapy 128 Melphalan 127 Peripheral Blood Stem Cell Transplantation 123 Busulfan 118 Bendamustine Hydrochloride 116 Granulocyte Colony-Stimulating Factor 113 Bortezomib 112 ibrutinib 111 Mycophenolic Acid 110 venetoclax 106 Whole-Body Irradiation 106 Tacrolimus 105 obinutuzumab 104 Gemcitabine 92 zanubrutinib 81 Specimen Handling 80 Cyclosporine 76

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × niraparib × Lymphoid × Clear all

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡